HSP90 inhibitors disrupt the structural stability of these signaling proteins, promoting their degradation via the ubiquitin–proteasome pathway, thereby inhibiting signaling and suppressing cancer cell growth [1]. The gene discussed is HSP90AA1; the disease is cancer.